JYNARQUE
PeakNDAORALTABLETPriority Review
Approved
Apr 2018
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JYNARQUE (tolvaptan) is an oral vasopressin V2 receptor antagonist approved in 2018 for autosomal dominant polycystic kidney disease (ADPKD). It works by blocking vasopressin signaling in the kidney's collecting duct, slowing cyst growth and disease progression. The drug represents a significant therapeutic advance in a rare genetic disorder with limited prior treatment options.
$0.076BPart D
Peak3.4 years to LOEProduct is at peak commercial stage with $76M in Part D spending, suggesting mature market presence but limited near-term growth upside for team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on JYNARQUE at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.